Video

Dr. Sledge on Using Tumor Heterogeneity to Guide Treatment in Breast Cancer

George W. Sledge, Jr., MD, professor of medicine, Stanford University School of Medicine, explains how tumor heterogeneity impacts patient care and research.

George W. Sledge, Jr., MD, professor of medicine, Stanford University School of Medicine, explains how tumor heterogeneity impacts patient care and research.

Sledge says within a primary breast cancer, the tumor can express different sensitivities. This brings up a challenging question for physicians about which sensitivity to target. Guidelines help physicians define the tumor type, Sledge says.

In the metastatic setting, significant differences can exist between the primary tumor and the first site of metastasis. This is due in part to the cancer changing in an attempt to resist therapy. Sledge says it is important to rebiopsy patients at the time of metastatic disease in order to better treat the cancer.

<<<

View more from the 32nd Annual Miami Breast Cancer Conference

Related Videos
Sagar D. Sardesai, MBBS
DB-12
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP